Grape King Bio Ltd (TPE:1707)
Taiwan · Delayed Price · Currency is TWD 89.30
-1.30 (-1.43%)
Aug 28, 2026, 1:30 PM CST
Grape King Bio Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10,122 | 10,252 | 11,160 | 10,635 | 10,391 | 9,798 | |
Revenue Growth | -6.93% | -8.14% | 4.93% | 2.35% | 6.05% | 6.87% |
Cost of Revenue | 2,686 | 2,555 | 2,502 | 2,099 | 1,909 | 1,942 |
Gross Profit | 7,436 | 7,697 | 8,658 | 8,536 | 8,482 | 7,856 |
Selling, General & Admin | 5,132 | 5,281 | 5,866 | 5,747 | 5,639 | 5,252 |
Research & Development | 269.04 | 274.66 | 291.91 | 289.55 | 289.88 | 292.23 |
Other Operating Expenses | -0.6 | -0.52 | 0.02 | 2.48 | 1.1 | 0.57 |
Operating Expenses | 5,400 | 5,555 | 6,158 | 6,039 | 5,930 | 5,544 |
Operating Income | 2,036 | 2,142 | 2,500 | 2,497 | 2,552 | 2,312 |
Interest Expense | -4.62 | -4.68 | -2.95 | -2.54 | -2.29 | -3.93 |
Interest & Investment Income | 47.26 | 46.15 | 49.97 | 47.6 | 19.92 | 6.29 |
Earnings From Equity Investments | 11.68 | 28.72 | 22.24 | 19.87 | 10.82 | 2.23 |
Currency Exchange Gain (Loss) | -1.33 | -1.33 | 7.38 | - | 11.63 | -2.24 |
Other Non Operating Income (Expenses) | 100.45 | 87.69 | 94.13 | 99.02 | 94.1 | 99.35 |
EBT Excluding Unusual Items | 2,189 | 2,298 | 2,671 | 2,661 | 2,686 | 2,413 |
Gain (Loss) on Sale of Investments | 0.71 | 0.71 | 0.9 | - | -1.91 | 0.8 |
Gain (Loss) on Sale of Assets | -1.07 | -1.07 | 0.62 | - | 3.76 | 0.82 |
Other Unusual Items | - | - | 1.18 | - | 0.11 | - |
Pretax Income | 2,189 | 2,298 | 2,673 | 2,661 | 2,688 | 2,415 |
Income Tax Expense | 417.67 | 436.77 | 502.15 | 519.11 | 518.19 | 466.92 |
Earnings From Continuing Operations | 1,771 | 1,861 | 2,171 | 2,142 | 2,170 | 1,948 |
Minority Interest in Earnings | -623.44 | -642.63 | -722.85 | -688.78 | -712.58 | -647.57 |
Net Income | 1,148 | 1,218 | 1,448 | 1,453 | 1,457 | 1,300 |
Net Income to Common | 1,148 | 1,218 | 1,448 | 1,453 | 1,457 | 1,300 |
Net Income Growth | -14.34% | -15.88% | -0.30% | -0.30% | 12.05% | 2.23% |
Shares Outstanding (Basic) | 148 | 148 | 148 | 148 | 148 | 148 |
Shares Outstanding (Diluted) | 149 | 149 | 149 | 149 | 149 | 148 |
Shares Change | 0.13% | -0.01% | 0.01% | 0.06% | 0.45% | 8.41% |
EPS (Basic) | 7.76 | 8.22 | 9.78 | 9.81 | 9.84 | 8.81 |
EPS (Diluted) | 7.69 | 8.17 | 9.71 | 9.74 | 9.78 | 8.76 |
EPS Growth | -14.40% | -15.86% | -0.31% | -0.41% | 11.64% | -5.71% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,498 | 1,734 | 1,249 | 1,932 | 2,504 | 2,267 |
Free Cash Flow Per Share | 10.03 | 11.63 | 8.38 | 12.96 | 16.80 | 15.28 |
Dividend Per Share | 6.000 | 6.000 | 6.900 | 6.900 | 6.900 | 6.100 |
Dividend Growth | 42.86% | -13.04% | 0% | 0% | 13.11% | -4.69% |
Gross Margin | 73.47% | 75.08% | 77.58% | 80.26% | 81.63% | 80.18% |
Operating Margin | 20.11% | 20.89% | 22.40% | 23.47% | 24.56% | 23.59% |
Profit Margin | 11.34% | 11.88% | 12.98% | 13.66% | 14.02% | 13.27% |
Free Cash Flow Margin | 14.80% | 16.92% | 11.19% | 18.17% | 24.09% | 23.14% |
EBITDA | 2,498 | 2,598 | 2,933 | 2,956 | 2,936 | 2,679 |
EBITDA Margin | 24.68% | 25.34% | 26.28% | 27.80% | 28.26% | 27.34% |
D&A For EBITDA | 462.48 | 456.2 | 433.33 | 459.76 | 384.63 | 367.68 |
EBIT | 2,036 | 2,142 | 2,500 | 2,497 | 2,552 | 2,312 |
EBIT Margin | 20.11% | 20.89% | 22.40% | 23.47% | 24.56% | 23.59% |
Effective Tax Rate | 19.08% | 19.01% | 18.78% | 19.51% | 19.28% | 19.34% |